Pfizer

Eye drugs list: Sodium hyaluronate, tafluprost, tobramycin uses

FDA · dry eyes · 5 min

This plan organizes a tightly sourced Eye drugs list around dry eyes, glaucoma, and eye infections. It keeps the focus on what the evidence confirms and avoids unsupported market or investment claims.

Danuglipron Phase 3 Watch After Pfizer’s Phase 2b Obesity Win

obesity · 6 min

Pfizer said its oral GLP-1 danuglipron met the primary endpoint in a Phase 2b obesity trial, showing a statistically significant change in body weight from baseline. The result strengthens the case for Pfizer's oral GLP-1 strategy and sets up investor and BD scrutiny around Phase 3 design, safety, and differentiation.

Pfizer's Danuglipron Hits Phase 2b Obesity Endpoint

obesity · 7 min

Pfizer said danuglipron, its oral GLP-1 receptor agonist, met the primary endpoint in a Phase 2b obesity trial with statistically significant weight loss versus baseline. The result strengthens the case for Danuglipron Phase 3 planning and gives BD and investor teams a fresh benchmark against other oral GLP-1 programs.

Pfizer berobenatide: VESPER-3 monthly GLP-1

obesity · 4 min

Pfizer's monthly GLP-1 RA berobenatide (acquired from Metsera) shows continued weight loss in VESPER-3 Phase 2b data. This analysis covers efficacy, safety, and strategic implications for pharma teams.

Pfizer Berobenatide Phase 2b Monthly Dosing

obesity · 4 min

Pfizer’s VESPER-3 Phase 2b showed up to 12.3% placebo-adjusted weight loss at week 28 with monthly berobenatide after weekly titration.

Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target?

FDA · non-small cell lung cancer · 5 min

While many drugmakers are focused on lung cancer for PD-1/VEGF bispecifics, emerging evidence shows the liver may offer higher value. This analysis covers the mechanism, key players, and strategic implications for pharma teams.

Rx Rundown: Pfizer, Hikma Pharmaceuticals, NewLimit — Drug Approvals & Catalyst Tracker

5 min

Pfizer, Hikma Pharmaceuticals, and NewLimit are at the center of recent FDA actions. This rundown covers approvals, withdrawals, and upcoming catalysts for pharma BD and investors.

Otsuka Voyxact Data and Pfizer AI Deal Tracker

IgA nephropathy · 8 min

Drug & pharma latest press release traffic this week clustered on two files: Otsuka’s Voyxact (sibeprenlimab-szsi) kidney-function data in IgA nephropathy, and Pfizer’s license deal with Chai Discovery for generative AI drug design. Here is the BD-relevant readout without the rumor layer.

China: The Innovation Factor – Implications for Pharma BD and Investors

6 min

China has emerged as a global innovation powerhouse, now leading in 37 of 44 critical technologies. This article examines what this means for pharmaceutical deal-making, investment decisions, and competitive strategy for BD teams and executives.

Pfizer sharpens prostate cancer case with Talzenna win — oncology

oncology · 5 min

Pfizer announced a Phase III win for Talzenna (talazoparib) plus Xtandi (enzalutamide) in metastatic castration-sensitive prostate cancer, setting up a potential broader label. This analysis covers the TALAPRO-3 results, implications for the prostate cancer treatment landscape, and key milestones for pharma teams and investors.

ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come

ASCO · oncology · 8 min

Structured plan for ASCO: Pfizer scores in lung, colorectal and prostate cancer but key readouts still to come

BBSW AI Solution Event: Daily Roundup

ai-ml-in-pharma · 8 min

Day 1 at BBSW AI Solution Summit 2026: AI moved from demos into discovery, trial operations, and regulatory workflows, while data quality and credibility evidence remained the binding constraints.